TKT and gastrointestinal stromal tumor: A phase II Study aiming to evaluate the efficacy and safety of nilotinib patients with gastrointestinal stromal tumors (GIST) resistant or intolerant to imatinib and or to 2nd-line tyrosine kinas (TK) inhibitor